Fundraising FoxRegeneron Ventures — Full Portfolio
8 tracked investments · listed companies and verified rows first
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)Alexander Marson(Founder)Kole Roybal(Founder)
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsLuma GroupOUP (Osage University Partners)SoftBank Vision Fund+4 more
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesViking GlobalAltitude Ventures Management, LlcCasdin Capital+5 more
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsFinchley Healthcare VenturesLongwood FundLuma GroupSofinnova VenturesBAM ElevateForbion+2 more
Netherlands-based developer of fully synthetic immune therapies against cancer and persistent viral infections using a synthetic long peptide platform.
Co-investorsCancer FocusInvest-NL
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+6 more
Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.
BiotechBoston, US
Tasuku Kitada(Executive Officer, Director, Promoter)inJacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in
BoardJeb Keiper(Director)inAla Alenazi(Director)inPegah Ebrahimi(Director)in
Co-investorsJIC Venture Growth InvestmentsKinnevikPlayground GlobalAmgen VenturesANRIFPV+3 more
Strand is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases.
AI & Machine LearningBiotechMedical DevicesBoston, US
Jacob Becraft(CEO, Co-Founder)inTasuku Kitada(President, Head of R&D, Co-founder)inRon Weiss(Scientific Co-founder)inDarrell J. Irvine(Scientific Co-founder)inPrashant Nambiar(Chief Scientific Officer)Ethan Cash(Senior Vice President, Head of Portfolio Management and Program Development)in
Co-investorsAtinum Investment Co. Ltd.FPVLG Technology VenturesPlayground GlobalPotentum PartnersAlix Ventures+5 more
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Co-Founder, President, CFO, COO)inDerek Jantz(Executive Officer)inCharles Gersbach(Co-Founder)inJohn McHutchison(CEO, Chairman of the Board)inDan McHugh(Co-Founder, Investor)inBlythe Sather(Executive Officer)in
Co-investorsDuke Capital PartnersHatteras Venture PartnersMission BiocapitalNew Enterprise Associates (NEA)Pappas CapitalRV Invest GmbH+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.